Advertisement
Per the distribution agreement, Lloyds Pharmacy will distribute RESPeRATEin 1,440 stores beginning in May 2008 and for a limited period will be theonly nation-wide UK retail chain to carry the product. As part of the launch,RESPeRATE, retailing at 199 pounds Sterling, will be prominently displayed aspart of Lloyds in store merchandising programmes. This prime position willallow consumers to learn more about RESPeRATE and interact with the device.Lloyds Pharmacy will also offer product demonstrations to instruct consumershow to successfully include RESPeRATE into their overall hypertensionmanagement regimen.
Advertisement
"With many of our shoppers looking for new ways to manage hypertensionwith a treatment that fits into their lifestyles, we are pleased to offerRESPeRATE as a complement to our existing line of innovative healthcareproducts and services," said Justin Woodward, senior marketing manager atLloyds Pharmacy.
"The full-chain launch of RESPeRATE at Lloyds Pharmacy clearlydemonstrates the broad appeal of our effective and truly natural device-guidedbreathing therapy for hypertension," said Erez Gavish, president and CEO ofInterCure. "Commanding a premium 199 pounds price point at this respectedretailer is yet another validation of the value of RESPeRATE in the managementof high blood pressure. Lloyds Pharmacy has built a strong reputation byeducating consumers and providing them with innovative healthcare productsthat meet their medical needs. RESPeRATE is a perfect fit for Lloyds Pharmacycustomers looking to take control of their hypertension with the help of theirtrusted community pharmacy."
Sixteen million adults in the UK suffer from high blood pressure. Leftuntreated, it may lead to heart attack, stroke and kidney or heart failure.
About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42billion hypertension industry with the world's first FDA-cleared, OTC bloodpressure treatment device, RESPeRATE(R) (http://www.resperate.com). In amarket where seven out of 10 hypertensives are NOT controlled despite theavailability of more than 100 blood pressure medications, RESPeRATE providesan effective non-drug therapy with no side effects.
RESPeRATE has gained widespread support of hypertension specialists andhas secured regulatory clearance in most key international markets. Tenseparate clinical studies have proven the device's efficacy and safety, andRESPeRATE is now featured in more than 20 popular and professional text booksincluding Mayo Clinic's On High Blood Pressure and the American HeartAssociation's Hypertension Primer.
With more than 100,000 units sold, thousands of supportive cliniciansworldwide and one of the world's most popular hypertension websites, InterCureis now introducing RESPeRATE into retail pharmacies to increase access tohypertension sufferers.
InterCure has an exciting product pipeline based on its broadly-patented"Device-Guided Breathing" technology platform. This technology enables asystematic reduction in sympathetic outflow of the autonomic nervous system,one of the key underlying causes of cardiovascular disease, insomnia andseveral other medical conditions.
About Lloyds Pharmacy
Lloyds Pharmacy has 1,700 pharmacies across the country. These are basedpredominantly in community and health centre locations. The company employsover 16,000 staff, of which 80 percent are women, and dispenses 120 millionprescript
